Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025
Bicara Therapeutics (NASDAQ:BCAX) had its price target raised by analysts at Wells Fargo & Company from $8.00 to $11.00. They now have an "equal weight" rating on the stock.
Bicara Therapeutics (NASDAQ:BCAX) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $30.00 price target on the stock.
Bicara Therapeutics GAAP EPS of -$0.67 [Seeking Alpha]
Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]